Brent Bankosky joins Tranzyme as VP
This article was originally published in Scrip
Tranzyme Pharma, a late-stage biopharmaceutical company focused on developing treatments for upper gastrointestinal motility disorders, has hired Brent Bankosky as vice-president of business development, succeeding Dr Jennifer Filbey. Mr Bankosky most recently served as senior director of global licensing and business development for Takeda.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.